2026-04-29T04:09:31Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/229712024-11-29T00:44:28Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Martínez-López, Icíar author Maurino, Jorge author Sanmartin-Fenollera, Patricia author Ontanon-Nasarre, Ana author Santiago-Perez, Alejandro author Moya-Carmona, Isabel author Gustavo Garcia-Collado, Carlos author Fernandez-Del Olmo, Raquel author Garcia-Arcelay, Elena author Sarmiento, Monica author Carreno, Agata author Perez-Encinas, Montserrat author 2020-06 Introduction: Hospital pharmacists are increasingly playing a critical role in the care of patients with multiple sclerosis (MS). However, little is known about their preferences and perspectives towards different attributes of disease-modifying therapies (DMTs). The objective of this research was to assess pharmacists ' preferences for DMT efficacy attributes. Methods: A multicenter, non-interventional, cross-sectional, web-based study was conducted. Preventing relapses, delaying disease progression, controlling radiological activity, and preserving health-related quality of life (HRQoL) and cognition were the attributes selected based on a literature review and a focus group with six hospital pharmacists. Conjoint analysis was used to determine preferences in eight hypothetical treatment scenarios, combining different levels of each attribute and ranking them from most to least preferred. Results: Sixty-five hospital pharmacists completed the study (mean age: 43.5 +/- 7.8 years, 63.1% female, mean years of professional experience: 16.1 +/- 7.4 years). Participants placed the greatest preference on delaying disease progression (35.7%) and preserving HRQoL (21.6%) and cognition (21.6%). Importance was consistent in all groups of pharmacists stratified according to demographic characteristics, experience, research background, and volume of patients seen per year. Conclusions: Understanding which treatment characteristics are meaningful to hospital pharmacists may help to enhance their synergistic role in the multidisciplinary management of patients with MS. Martínez López I, Maurino J, Sanmartin-Fenollera P, Ontanon-Nasarre A, Santiago-Perez A, Moya-Carmona I, et al. Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis. Pharmacy. 2020 Jun;8(2):61. http://hdl.handle.net/20.500.13003/10487 https://hdl.handle.net/20.500.12105/22971 32272683 10.3390/pharmacy8020061 2226-4787 Pharmacy 552756500049 L632084844 Multiple sclerosis Pharmacist Preferences Disease-modifying therapy Disease progression Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis